These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 25901683)

  • 1. TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
    Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new way to target p53-defective colorectal cancer.
    Liu Y; Wang L; Lu X
    Future Oncol; 2015; 11(23):3101-4. PubMed ID: 26549592
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug resistance and new therapies in colorectal cancer.
    Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
    World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy.
    Errico A
    Nat Rev Clin Oncol; 2015 Jul; 12(7):374. PubMed ID: 25985938
    [No Abstract]   [Full Text] [Related]  

  • 6. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
    Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
    Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
    Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
    Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
    Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
    Res Sq; 2024 Jan; ():. PubMed ID: 38260385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CKIα ablation highlights a critical role for p53 in invasiveness control.
    Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y
    Nature; 2011 Feb; 470(7334):409-13. PubMed ID: 21331045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly.
    Frischknecht L; Britschgi C; Galliker P; Christinat Y; Vichalkovski A; Gstaiger M; Kovacs WJ; Krek W
    Sci Rep; 2019 May; 9(1):7779. PubMed ID: 31123282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8-Acetonyldihydronitidine inhibits the proliferation of human colorectal cancer cells via activation of p53.
    Zhou J; Li Z; Zhang J; Wang H; Yin S; Du J
    Eur J Pharmacol; 2019 Jul; 854():256-264. PubMed ID: 30928633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the Pharmacokinetics and Antitumor Activity of an α-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain.
    Gallo F; Korsak B; Müller C; Hechler T; Yanakieva D; Avrutina O; Kolmar H; Pahl A
    J Med Chem; 2021 Apr; 64(7):4117-4129. PubMed ID: 33755471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.
    Yoon H; Liyanarachchi S; Wright FA; Davuluri R; Lockman JC; de la Chapelle A; Pellegata NS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15632-7. PubMed ID: 12438652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.
    Liu Y; Chen C; Xu Z; Scuoppo C; Rillahan CD; Gao J; Spitzer B; Bosbach B; Kastenhuber ER; Baslan T; Ackermann S; Cheng L; Wang Q; Niu T; Schultz N; Levine RL; Mills AA; Lowe SW
    Nature; 2016 Mar; 531(7595):471-475. PubMed ID: 26982726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
    Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
    Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.